
The CHMP recommended Gazyva/Gazyvaro for some adults with active lupus, with a European Commission decision expected soon.
Roche said the European Medicines Agency’s medicines committee recommended Gazyva/Gazyvaro as an add-on treatment for adults with moderate-to-severe, active systemic lupus erythematosus despite standard therapy. A final European Commission decision is expected in the near future.
The recommendation is based on the phase III ALLEGORY trial. At 52 weeks, 76.7% of patients receiving the drug plus standard therapy achieved at least a four-point improvement on the SLE Responder Index, compared with 53.5% of those given placebo plus standard therapy.
Roche said the treatment also performed better across key secondary measures, including sustained steroid reduction and time to a first disease flare. The company reported no new safety signals in the study.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.